EXISTING — Your Next Action block (unchanged)
Your Next Action
Start here. Do not move to another finding until this decision is defensible.
CRITICAL
Evidence packages cannot be produced on-demand
Audit responses indicate evidence would require reconstruction under inspection conditions. This is the primary citation trigger for FDA Form 483 observations. An inspector who asks for evidence and receives a promise to reconstruct it has grounds to escalate immediately.
You cannot produce this record under inspection conditions.
Get the record that defends this decision — $149 →
Inspection-ready. Specific to this decision. Delivered in minutes.
NEW — Redacted record preview (added below the Your Next Action block)
What the $149 record looks like
An inspection-readable Inspection Response Record. Generated specific to your decision, your evidence, and your authorization logic.
Inspection Response Record
Authorization Record — Sample
IRR-████-████
Page 1 of 4
Decision Statement
Authorization to release Batch █ following the deviation documented in Investigation █, having determined that product safety, identity, strength, quality, and purity are not impacted.
Evidence Considered
- Cleaning verification swab results (USP <1072>) — within acceptance criteria
- Residue analysis at █ ppm — below qualification threshold
- Three subsequent compliant batches manufactured under same conditions
- Operator retraining records dated █
Authorization Rationale
The deviation occurred during routine cleaning verification and was contained to a single equipment train. The corrective action was implemented prior to the next batch and verified through three subsequent in-spec batches. The cumulative evidence demonstrates the deviation did not affect product attributes, and the corrective action prevents recurrence. This decision is supported by the documented evidence above, was reviewed against ICH Q9 risk principles, and is authorized under the responsibilities defined in 21 CFR 211.22.
Anticipated Inspector Challenge
"How was the determination of 'no impact on product safety, identity, strength, quality, or purity' made?" — Answered in Section 4: Risk Evaluation, with reference to the documented evidence in Section 2.
PREVIEW
Sample fragment shown. Names, batch IDs, and investigation numbers are redacted in this preview. Your record is generated specific to your decision.
EXISTING — Additional Findings (with contrast fix)
Additional findings — address after your first decision is closed
HIGH
Evidence exists but reasoning or ownership is implicit
Evidence without explicit ownership or governing logic creates two-point exposure. An inspector who can see the evidence but cannot trace who reviewed it and why will cite both the gap and the absence of accountability.
HIGH
Risk prioritization not calibrated to inspection frequency
Internal risk frameworks consistently underweight areas inspectors actually cite. If your risk matrix doesn't reflect current enforcement patterns, you will be surprised by what inspectors ask about.